# Signals Article: Putative Target P01160 for Atrial Fibrillation
Background
Atrial fibrillation (AF) is the most common cardiac arrhythmia, characterized by irregular and often rapid heart rate. It can lead to significant morbidity, including stroke and heart failure. Despite its prevalence, the molecular mechanisms underlying AF are not fully understood, and current treatments have limitations. Identifying novel molecular targets could enhance therapeutic strategies for managing AF.
Data-mining rationale
In a recent reanalysis effort, UniProt entry P01160 was identified as a putative target for AF. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database, specifically datasets GDS:200299292, GDS:200297444, GDS:200289211, GDS:200235307, and GDS:200216168. Although P01160 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing P01160 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of P01160's potential as a target for AF. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of P01160 as a target for AF, several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of AF. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of P01160. If validated, assessing the druggability of P01160 via DGIdb and ChEMBL will be crucial for potential therapeutic development.